Recent Acquisition Has Strengthened Company’s Healthcare Product Offering
Evonik held an open house today of its new Birmingham Laboratories facility, located at 750 Lakeshore Parkway and 756 Tom Martin Drive in Birmingham, Ala., with officials praising the hard work and dedication of its employees. The company’s acquisition of the assets of SurModics Pharmaceuticals, Inc. helped strengthen Evonik’s healthcare product portfolio.
“We want to recognize the outstanding work of our employees at Birmingham Laboratories,” said Dr. Reiner Beste, Health & Nutrition Business Unit President. “Their hard work and dedication are invaluable assets to our business. On behalf of Evonik, I would like to thank each and every employee for their efforts.”
Evonik acquired the assets of SurModics Pharmaceuticals Inc., a subsidiary of SurModics Inc., and named the facility Birmingham Laboratories. The facility specializes in drug delivery technologies and manufacturing for pharmaceutical, biotechnology, and medical device companies. Beste noted the acquisition demonstrates Evonik’s commitment to expanding its healthcare product offering.
“This is a great strategic move for our business as it gives us ownership of SurModics Pharmaceutical Inc’s pharmaceutical products including parenteral dosage forms services and bioresorbable polymers business. This will help solidify us as one of the world’s leading chemical providers to the health care industry,” added Beste.
The open house included a sign unveiling, facility tour and an employee luncheon. Evonik Degussa Corporation President Tom Bates, Dr. Reiner Beste, and Healthcare Business Line Senior Vice President Jean-Luc Herbeaux were among the dignitaries attending the event.
“I am very pleased to welcome all the former SurModics Pharmaceuticals, Inc. employees to the Evonik family here at Birmingham Laboratories,” said Art Tipton, site manager of Birmingham Laboratories. “This open house is a great opportunity for us to get to know the employees and assure everyone we will continue doing business without skipping a beat.”
Together with the open house, Birmingham Laboratories also hosted the BioAlabama 2012 Annual Meeting from 3:00 p.m. to 4:45 p.m. The Biotechnology Association of Alabama is a statewide organization representing Alabama’s bio-related industries, research scientists, clinicians and business professionals who strive to promote biotechnology innovation.
For additional information about Evonik in North America, please visit our website: www.evonik.com/north-america.
Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Evonik benefits specifically from its innovative prowess and integrated technology platforms.
Evonik is active in over 100 countries around the world. In fiscal 2011 more than 33,000 employees generated sales of around €14.5 billion and an operating profit (adjusted EBITDA) of about €2.8 billion.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.